Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE)

A randomized phase III trial commenced in Japan in February 2018. Definitive chemoradiotherapy (CRT) with cisplatin plus 5-fluorouracil is the current standard treatment for locally advanced unresectable esophageal carcinoma. The purpose of this study is to confirm the superiority of induction chemo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Japanese journal of clinical oncology 2019-12, Vol.49 (11), p.1055-1060
Hauptverfasser:	Terada, Mitsumi, Hara, Hiroki, Daiko, Hiroyuki, Mizusawa, Junki, Kadota, Tomohiro, Hori, Keisuke, Ogawa, Hirofumi, Ogata, Takashi, Sakanaka, Katsuyuki, Sakamoto, Takeshi, Kato, Ken, Kitagawa, Yuko
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemoradiotherapy - methods Cisplatin - therapeutic use Combined Modality Therapy - methods Docetaxel - therapeutic use Esophageal Neoplasms - drug therapy Female Fluorouracil - therapeutic use Humans Induction Chemotherapy - methods Japan Male Middle Aged Progression-Free Survival Squamous Cell Carcinoma of Head and Neck - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!